A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, 5-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

被引:74
作者
Hassan-Alin, M [1 ]
Andersson, T
Niazi, M
Röhss, K
机构
[1] AstraZeneca R&D, Expt Med, S-43183 Molndal, Sweden
[2] AstraZeneca LP, Expt Med, Wilmington, DE USA
关键词
pharmacokinetics; S-omeprazole; R-omeprazole; racemic orneprazole;
D O I
10.1007/s00228-004-0841-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To investigate the pharmacokinetics of S-omeprazole (esomeprazole), R-omeprazole and racemic omeprazole following single and repeated oral doses of 20 mg and 40 mg of each compound in healthy male and female subjects. Methods: In an open, randomised, three-way, cross-over study, 12 subjects received 20 mg and another 12 subjects received 40 mg S-omeprazole, R-omeprazolc and racemic omeprazole as oral solutions once daily for 5 days, separated by washout periods of at least 10 days. Blood samples were taken for analysis pre-dose and at selected time points during a 12-h period following drug administration on study day 1 and day 5. Pharmacokinetic parameters of S-omeprazole, R-omeprazole. racemic omeprazole and the two main metabolites (5-hydroxy and sulphone) were calculated using noncompartmental analysis. Results: Following the 20-mg dose of each compound, values of the total area under the plasma concentration-time curve (AUC) were 1.52, 0.62 and 1.04 mu mol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1. Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 mu mol h/l. Corresponding values after the 40-mg doses were 3.88, 1.39 and 2.44 ltrnol h/l on day 1 and 9.32, 1.80 and 5.79 mu mol h/l on day 5. Conclusion: Treatment with S-omeprazole (esomeprazole; 20 mg and 40 mg) resulted in higher AUC values than with either R-omeprazole or racemic omeprazole after both single and repeated doses due to a lower metabolic rate of S-omeprazole than R-omeprazole and, consequently, racemic omeprazole. S-Omeprazole, R-omeprazole and the racemate were well tolerated.
引用
收藏
页码:779 / 784
页数:6
相关论文
共 14 条
[1]  
Äbelö A, 2000, DRUG METAB DISPOS, V28, P966
[2]  
ANDERSON H, 1991, J STRATEGIC SYSTEMIC, V10, P20, DOI DOI 10.1521/JSST.1991.10.1.20
[3]   EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[4]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[5]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[6]   Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole [J].
Andersson, T ;
Hassan-Alin, M ;
Hasselgren, G ;
Röhss, K ;
Weidolf, L .
CLINICAL PHARMACOKINETICS, 2001, 40 (06) :411-426
[7]  
ANDERSSON T, 2000, GASTROENTEROLOGY S2, V118, P1210
[8]  
ANDERSSON T, 1991, THESIS GOTEBORG U
[9]   Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [J].
Hassan-Alin, M ;
Andersson, T ;
Bredberg, E ;
Röhss, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) :665-670
[10]   Importance of pH control in the management of GERD [J].
Hunt, RH .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (07) :649-657